Phaseline

Targets › PPOX

PPOX (Protoporphyrinogen oxidase): drug programs, companies and trials

12 programs from 11 companies in 13 trials: 6 Phase 1, 4 Phase 2, 2 Phase 3, 1 Phase 4; Oncology, Immunology; next expected readout Nov 2026.

Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX. (UniProt, P50336)

Open in Phaseline: the race on PPOX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Psoriasis Treatment Center of Central New JerseyAmeluz 10% Topical Gel
Aminolevulinic acid (ALA) for photodynamic therapy; ALA is converted to protoporphyrin IX
PPOXPhase 4Actinic KeratosesNov 2026
Sun Pharmaceutical IndustriesReformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA
Aminolevulinic acid prodrug for photodynamic therapy; converted to protoporphyrin IX for p
PPOXPhase 3Actinic KeratosisJan 2027
Lee's Pharmaceutical5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution
5-ALA is a prodrug that accumulates protoporphyrin IX in tumor cells; fluorescence is used
PPOXPhase 35-aminolevulinic AcidDec 2027
Case Comprehensive Cancer CenterALA (Levulan)
Prodrug for photodynamic therapy; metabolized to protoporphyrin IX to generate reactive ox
PPOXPhase 2Basal Cell CarcinomaSep 2027
Henry Ford Health System5-Aminolevulinic acid Hydrochloride (Gliolan®)
Fluorescent imaging agent that induces protoporphyrin IX accumulation for photodynamic dia
PPOXPhase 2Upper Tract Urothelial Carcinoma; Kidney CancersDec 2027
University Hospital, Lille5-Aminolevulinic Acid (5-ALA)
Photosensitizer that accumulates in tumors and generates singlet oxygen upon light activat
PPOXPhase 2Mesotheliomas Pleural–
Nathalie Zeitouniaminolevulinic acid HCL (ALA)
Prodrug converted to protoporphyrin IX for photodynamic therapy
PPOXPhase 1Basal Cell Carcinoma (BCC)Dec 2026
Shayan Moosa, MD5-ALA
Photosensitizer prodrug (converts to protoporphyrin IX); used in sonodynamic therapy to ge
PPOXPhase 1Recurrent GlioblastomaDec 2026
Sun Pharmaceutical IndustriesLevulan Kerastick (reformulated)
5-aminolevulinic acid (ALA) prodrug for photodynamic therapy
PPOXPhase 1Actinic Keratosis (AK)Dec 2026
Universität MünsterGliolan (5-Aminolevulinic acid)
Protoporphyrin IX precursor; photosensitizer for radiodynamic therapy
PPOXPhase 1GlioblastomaJan 2028
Roswell Park Cancer InstituteAminolevulinic Acid
Photosensitizing agent converted to protoporphyrin IX in cancer cells; emits red fluoresce
PPOXPhase 1Locally Advanced Colorectal CarcinomaJun 2029
Hemerion Therapeutics5-ALA HCl intraoperative Photodynamic Therapy (PDT)
Photodynamic therapy using 5-aminolevulinic acid as a photosensitizer
PPOXPhase 1Primary Glioblastoma–

Conditions

Actinic Keratosis (AK) (1) Basal Cell Carcinoma (BCC) (1) Primary Glioblastoma (1) Actinic Keratosis (1) Basal Cell Carcinoma (1) Actinic Keratoses (1) Glioblastoma (1) 5-aminolevulinic Acid (1) Upper Tract Urothelial Carcinoma (1) Kidney Cancers (1) Recurrent Glioblastoma (1) Mesotheliomas Pleural (1)

Modalities

small molecule (9), antibody (1)

Companies

Sun Pharmaceutical Industries (2) Nathalie Zeitouni (1) Hemerion Therapeutics (1) Case Comprehensive Cancer Center (1) Psoriasis Treatment Center of Central New Jersey (1) Universität Münster (1) Lee's Pharmaceutical (1) Henry Ford Health System (1) Shayan Moosa, MD (1) University Hospital, Lille (1) Roswell Park Cancer Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.